The RIGHT Trial: Rapid Intervention with Glyceryl trinitrate (GTN) in Hypertensive stroke Trial

ISRCTN	ISRCTN66434824
ClinicalTrials.gov identifier	
Public title	The RIGHT Trial: Rapid Intervention with Glyceryl trinitrate (GTN) in Hypertensive stroke Trial
Scientific title	Determining the potential of ambulance-based randomised controlled trials in patients with hyperacute stroke: assessment of glyceryl trinitrate in lowering blood pressure
Acronym	RIGHT
Serial number at source	N/A
Study hypothesis	1. To assess the feasibility of performing an ambulance-based trial in patients with hyperacute stroke, a key question for the future testing of potential interventions aimed at neuroprotection and physiological control 2. To assess the effect of glyceryl trinitrate (GTN) on blood pressure (BP) in this setting
Ethics approval	Ethics approval pending from the Nottingham Research Ethics Committee 2 as of 18/02/08 (ref: 08/H0408/18).
Study design	Ambulance-based, single city, single-blind, randomised controlled trial with blinded outcome assessment.
Countries of recruitment	United Kingdom
Disease/condition /study domain	Acute stroke

Participants - inclusion criteria	1. Adult patients of either sex; greater than 40 years of age 2. Paramedic assessment of stroke on basis of positive 'Face & Arm weakness and Speech abnormality Test (FAST) in the context of a call to a patient with a 'possible acute stroke' 3. Event less than 4 hours of onset (sleep stroke - onset as bed time) 4. High systolic BP (greater than 140 mmHg)
Participants - exclusion criteria	1. No consent/assent is available 2. GTN is indicated (e.g. concurrent angina) 3. GTN is contraindicated (e.g. dehydration, hypovolaemia) 4. Aged less than 40 years 5. Coma; Glasgow Coma Scale (GCS) score less than or equal to 8 6. History of seizures 7. Non-ambulatory pre-morbidly (modified Rankin scale of greater than 2) 8. Hypoglycaemia (if glucose tested) 9. Patients from a nursing home
Anticipated start date	01/03/2008
Anticipated end date	31/12/2009
Status of trial	Ongoing
Patient information material	Not available in web format, please use the contact details below to request a patient information sheet.
Target number of participants	80
Interventions	Transdermal GTN (5 mg) or no patch. Total duration of treatment: 7 days Total duration of follow up: 90 days
Primary outcome measure(s)	To assess the feasibility of using the ambulance service to test and deliver treatment for stroke in the hyperacute setting, will be measured as effects of GTN on blood pressure at 2 hours post-treatment.
Secondary outcome measure(s)	To assess the effects of GTN on: 1. Blood pressure 2. Pulse pressure (PP) 3. Rate pressure product (RPP) 4. Surrogate markers of efficacy in blood in the hyperacute setting Measured in hospital, day 7/discharge/death, and day 90.

Sources of funding	No funding as of 19/02/08
Trial website	
Publications	
Contact name	***Prof Philip Bath***
Address	*Division of Stroke Medicine* University of Nottingham Clinical Sciences Building City Hospital Hucknall Road
City/town	Nottingham
Zip/Postcode	NG5 1PB
Country	United Kingdom
Tel	+44 (0)115 823 1765
Fax	+44 (0)115 823 1767
Email	philip.bath@nottingham.ac.uk
Sponsor	University of Nottingham (UK)
Address	*c/o* Mr Paul Cartledge Head of Research Grants and Research Innovation Services King's Meadow Campus Lenton Lane
City/town	Nottingham
Zip/Postcode	NG7 2NR
Country	United Kingdom
Tel	+44 (0)115 951 5670
Email	Paul.cartledge@nottingham.ac.uk
Sponsor website:	http://www.nottingham.ac.uk/
Date applied	18/02/2008
Last edited	09/05/2008